Abstract: Protein stability and ligand-binding affinity measurements are widely required for the formulation of biopharmaceutical proteins, protein engineering and drug screening within life science research. Current techniques either consume too much of often precious biological or compound materials, in large sample volumes, or alternatively require chemical labeling with fluorescent tags to achieve measurements at submicrolitre volumes with less sample. Here we present a quantitative and accurate method for the determination of protein stability and the affinity for small molecules, at only 1.5-20 nL optical sample volumes without the need for fluorescent labeling, and that takes advantage of the intrinsic tryptophan fluorescence of most proteins. Coupled to appropriate microfluidic sample preparation methods, the sample requirements could thus be reduced 85,000-fold to just 10 8 molecules. The stability of wild-type FKBP-12 and a destabilizing binding-pocket mutant are studied in the presence and absence of rapamycin, to demonstrate the potential of the technique to both drug screening and protein engineering. The results show that 75% of the interaction energy between FKBP-12 and rapamycin originates from residue Phe99 in the binding site.
Introduction
There is a significant need for high-throughput techniques that are capable of measuring dissociation constants for combinatorially-derived compound libraries, towards drug susceptible protein targets. 1 The need is increasingly pressing because previously containable pathogenic organisms such as Mycobacterium tuberculosis, the seventh leading cause of death worldwide, 2 Clostridium difficiles, and Streptococcus aureus continue to develop multidrug resistance. At the same time, new targets are being identified through genome sequencing and proteomics at an increasing pace. 3, 4 Identifying new drug leads from large chemical libraries requires sensitive high-throughput assays for measuring protein-drug interactions. Existing approaches rely heavily on microplate-based assays, use large quantities of precious protein target and drug compound samples, require high capital investment in automation platforms, have increased errors due to multiple small volume injections, and are prone to evaporation of sample liquids. 5 Furthermore, most assays are not generally applicable to measuring a multitude of protein-drug interactions. There is therefore a need for smaller volume assays that conserve samples and can be operated with greater throughput and accuracy.
We have previously established a microplatebased technique for measuring protein stability to denaturants, the effects of mutations, complex denaturation pathways, and ligand affinities, based on the classical measurement of intrinsic protein fluorescence, 6, 7 removing the need for extrinsic fluorophores such as 1-anilino-8-naphthalene-sulfonate (ANS) used in earlier experiments at the microplate scale, 8 but which can alter the solubility and stability of proteins and also their interactions with other molecules. While this technique improved throughput considerably over autotitration methods in fluorometers, 9 there is a further need for increased throughput and decreased sample volume to match the increasing size and small-scale syntheses of combinatorial compound libraries in drug discovery, 10 for the evolutionary engineering of proteins, 11 and for protein bioprocess formulation. 12 Towards this aim, microfluidic techniques have been described previously for monitoring the denaturation or refolding of proteins by the measurement of extrinsically added fluorophores, 13 or Forster resonant energy transfer (FRET) with fluorescent protein labels. 14, 15 The binding affinity between two proteins has also been achieved using two-photon excitation and a fluorescent label. 16 However, the addition of fluorescent labels to proteins can affect their ligand binding, solubility and stability, and it is also difficult to ensure the attachment of only a single label per protein molecule. 17, 18 The measurement of intrinsic protein fluorescence has also been demonstrated previously in microchannels for the label-free detection of proteins and their conformational changes, by using lasers [19] [20] [21] or light-emitting diodes (LED's) 22, 23 for the excitation of samples.
However, these techniques have not yet been sufficiently accurate to obtain thermodynamic parameters such as the free-energy of protein unfolding, as is required for use in drug-discovery, formulation or protein engineering applications. More recently, fluorescence lifetime microscopy has been used to detect the interaction between two label-free proteins at the single molecule level. 17 The sensitivity of this technique took advantage of the interaction of two large proteins beta-galactosidase (116 kDa) and an antibody (ca. 150 kDa). However it is not yet able to determine dissociation constants for proteins, measure the conformation and stability of proteins, or detect and quantify the interaction of a protein with small drug-like molecules or ligands. Greater sensitivity at the single molecule level has been achieved recently for the measurement of conformational changes by fluorescence correlation spectroscopy, though this again relies upon the labeling of proteins with a strong fluorophore such as Alexa or AttoOxa11 dyes, 24, 25 or the use of highly fluorescent proteins such as yellow fluorescent protein (YFP). 26 Here we present a microfluidic measurement technique that enables the thermodynamic stability of reversibly unfolding proteins, and the affinity of a small molecule drug compound for a target protein, to be determined using small samples and with high precision. The technique measures the intrinsic fluorescence intensity of proteins under a range of denaturing conditions to determine the stability of the target protein. This is repeated in the presence of a drug compound and the resulting stabilization used to estimate the binding affinity of the compound to the protein. We demonstrate this technique for the first time in a microfluidic system by measuring the binding of rapamycin to the 12 kDa FK506 binding protein (FKBP-12), which is a target for prostate cancer treatment, 27 immunosuppression 28, 29 and most recently for aging in mice. 30 We also compare the results with those obtained using an equivalent microplate-based assay. FKBP is a peptidyl-prolyl isomerase enzyme and also a cytosolic immunophilin found in many mammalian cell types. In the latter role, it is known to inhibit T-cell proliferation via the calcineurin-dependent signal transduction pathway, in the presence of FK506 or rapamycin. 31 For this purpose, rapamycin and FK506 are both used as immunosuppressants to minimize organ rejection after transplant surgery, or in patients that suffer from autoimmune disorders. The structure of native human FKBP-12 has been obtained both in the presence and absence of rapamycin, by X-ray crystallography 32 and NMR. 33, 34 The native protein contains an amphiphilic five-stranded antiparallel b-sheet packed against an amphiphilic a-helix via a hydrophobic core. The structure forms a large hydrophobic binding pocket to which rapamycin associates with high affinity (Fig. 1) . It has been shown previously to denature in a simple two-state transition 35 which apparently remains two-state when the native state is stabilized by the association of rapamycin, 36 and also for a considerable series of destabilizing and stabilizing mutations. 37 Here we have used the new microfluidic technique for the measurement of protein stability and rapamycin dissociation constants for the wild-type FKBP-12, and also for a previously unpublished mutant of FKBP-12 (F99L). Residue Phe99 is in the binding site for rapamycin ( Fig. 1 ) and is also involved in protein stabilization. We use the free energies determined by the capillary-scale technique in a double-mutant cycle type of analysis to determine the intermolecular coupling energy between rapamycin and Phe99.
To demonstrate our nanolitre-scale optical measurement advances we have used microlitre-scale equipment for the sample preparation and handling. However, our new technique demonstrates the potential for rapid drug, or protein stability screening by achieving a reduction in sample optical measurement volume from 260 lL in microplates, down to 1.5-20 nL in the microfluidic system, and a limit of detection reduced over 85,000-fold from 1.2 Â 10 13 in microplates to 1.4 Â 10 8 molecules in the microfluidic system. The technique is therefore suitable for coupling directly to nanolitre volume microfluidic devices for sample preparation and handling.
Results and Discussion
The microcapillary-based fluorometer we designed and built is shown schematically in Figure 2 (a,b) and the set up described in detail in the "Methods" section. Figure 2 (c) shows the raw PMT/PD ratio throughout a cycle of preparation, sample measurement and cleaning. The signal is stable for the initial buffer measurement, and after cleaning and reverting to buffer, the same signal returns, indicating complete removal of any protein that binds to the capillary surface over prolonged measurement times. The sample measurement time was deliberately extended in the cycle shown in Figure 2 (c) to demonstrate both the signal stability and also to show that the cleaning cycle is capable of removing protein from the capillary even for much longer exposure times than are required for accurate measurement. Occasional peaks are observed when the air is passed through the capillary. These are due to the air de-wetting the capillary surface and pushing out the resulting water droplets. The sensitivity, linearity, and dynamic range of the capillary based fluorometer was determined from the fluorescence intensities of BSA solutions at different protein concentrations, as shown in Figure 3 . The fluorescence emission was linearly proportional to the protein concentration with an R 2 of 0.994, and a standard error for each measurement of 0.015 RFU at above 1.5 lM BSA (from 100 laser pulses). The dynamic range of the linear response was 0.15 lM (0.01 mg/mL) to at least 75 lM (5 mg/mL) of BSA, corresponding to 0.45 to 225 lM tryptophan residues. The limit of detection was 0.15 lM BSA, and the signal-to-noise based on the standard deviation value ranged from 1.27 at 0.15 lM to 1568 at 75 lM BSA. The background fluorescence of the buffer was subtracted from all measurements and had a relative fluorescence intensity of 16.15 with a signal-to-noise of 323. To maintain the dynamic range and sensitivity it was necessary to alter the voltage applied to the PMT from 500 V for measurements between 1.5 lM and 75 lM BSA, to 600 V for less than 1.5 lM. The higher PMT voltage resulted in an increased (electronic) noise-induced measurement error. The limit of detection obtained in the capillary technique is compared to that obtained in a microplate in Table I . While the microplate reader was able to detect approximately half the concentration of BSA, the volume required was over 10 5 times greater than for the capillary technique. This gave a limit of detection of 1.4 Â 10 8 protein molecules in the capillary, which is 85,000-fold lower than for the microplate reader.
BSA was used initially to optimize the capability of the technique to obtain thermodynamic parameters from the equilibrium denaturation curves of proteins. The effect of urea denaturant concentration upon the measured fluorescence intensity of a 7.14 lM BSA solution at pH 7.2 is shown in Figure 4 for both the capillary-based and microplate methods. The raw data in Figure 4 (a) demonstrate the need for continuously monitoring the incident laser intensity with a photodiode (PD) and also illustrate the good signal-to-noise obtained with BSA. Figure 4(b) shows the time-dependence of the processed data as each sample enters the optical measurement zone. These data are then used to obtain the plot, in Figure 4(c), of denaturant versus fluorescence. A sharp sigmoidal transition is observed, as expected for the cooperative two-state unfolding of proteins upon addition of a chemical denaturant. 39 The thermodynamic parameters obtained by fitting the data to Eqs. (2) and (3) are shown in Our main aim was to demonstrate the use of a capillary-based fluorescence technique to obtain dissociation constants for compounds binding to a protein target of interest. The principle for determining dissociation constants from a change in protein stability has been demonstrated previously, 41 and is shown in Figure 5 using FKBP-12 as an example. This method is particularly useful for characterizing very tightly binding ligands and also for compounds that equilibrate slowly between bound and unbound forms. Chemical denaturation of wild-type and the mutant FL99 of FKBP-12 by guanidine hydrochloride (GdnHCl) was carried out in a microplate using our previous technique 6 and the same samples then measured directly afterwards using the capillary technique. The denaturation curves for wild-type FKBP-12 are compared directly in Figure 6 and show very good agreement between those measured in microplates and those made using the capillarybased technique. The raw data in Figure 6 (a) again demonstrate the need for continuously monitoring the incident laser intensity with a PD and also illustrate the good signal-to-noise obtained. The curves for the F99L mutant are also compared in Figure 7 . The sharp sigmoidal transition, expected for cooperative two-state unfolding, was observed in all cases.
Tables II and III display the thermodynamic parameters obtained from each curve and also compares them to known values from the literature. As expected, the stability of both the wild-type FKBP-12 and the mutant F99L increase in the presence of rapamycin. For wild-type the unfolding free energy increases by between 3 and 4 kcal mol À1 , whereas for F99L an increase of only 1.15 kcal mol À1 is observed indicating that the mutation affects the binding affinity of the rapamycin. The stability of the native protein is also decreased by 0.92 kcal The transition midpoints show very good agreement at all scales of measurement and show only a slight decrease in precision from 0.005 to 0.01 and 0.02 M GdnHCl for wild type at the respectively smaller scales. The m-values for equilibrium denaturation curves typically have the greatest errors which are the dominant contribution to errors in the calculated unfolding free energy. The m-values at different scales agree well within error, although for wild-type FKBP-12 in the absence of rapamycin the value in the capillary method is slightly lower than expected and this is reflected also in the lower free energy of unfolding obtained. The precision of the m-values obtained can in all cases typically be improved by either more repeats at each concentration or by a greater number of data points obtained for each curve, whereas the fluorescence measurements themselves have similar standard deviations for each method. However, a small systematic error associated with the capillary method itself cannot be ruled out, perhaps due to interaction with the capillary which has a greater surface-to-volume ratio than microplates or cuvettes. Photobleaching in the capillary does not occur at the flowrates used as the sample can only be excited once given the 200 lm laser spot and 1 kHz laser pulsing. Photobleaching was only observed at flowrates up to 1 lL min À1 (see Supporting Information Fig. S1 ).
Ligand dissociation constants can be obtained by measuring the free-energy of denaturation for native proteins in the presence and absence of the ligand. 45 The dissociation constants for rapamycin binding to both wild-type and F99L FKBP-12, derived using the capillary technique, are compared 40, 43, 44 The microplate-based fluorescence technique gave a value of 12.8 nM, and the capillary technique gave 7.4 nM, both consistent with the existing literature data. This demonstrates that the capillary technique can obtain useful dissociation constant measurements using significantly reduced quantities of sample. The dissociation constant obtained for rapamycin and the F99L mutant of FKBP-12 was determined here for the first time to be 1.8 lM using the capillary technique, showing a 240-fold loss of affinity relative to wild-type. The intermolecular coupling energy between rapamycin and the mutated phenylalanine residue in FKBP-12 could also be calculated from the free-energies determined in the capillary by using a double-mutant cycle analysis 46 where the interaction energy, DGint, is given by DGint ¼ DG FL99, rap À DG FL99 À DG rap þ DG wt . The interaction energy thus determined does not include the loss of protein stability resulting from the FL99 mutation, but reports only on the free energy for the interaction of rapamycin with the atoms removed by mutation. This interaction energy was found to be 3.0 6 1.3 kcal mol À1 , which is a significant proportion of the total interaction of 4.05 kcal mol À1 between FKBP-12 and rapamycin. It is remarkable that at least 50% of the interaction energy should be lost upon mutation of the Phe99 residue to leucine given that it contributes to only 3% of the FKBP-12 protein surface area that becomes solvent excluded upon binding to rapamycin.
Materials and Methods
Rapamycin was from LC Laboratories (Woburn, MA). All other reagents were from Sigma-Aldrich. Wild-type FKBP-12 and the F99L mutant were expressed and purified from a GST-FKBP fusion gene of the pGST-FKBP-12 plasmid in E. coli BL21 cells as described previously. 36 
Capillary-based fluorescence measurement
A 266 nm, 5 mW, 1 kHz pulsed QUV266-02 UV laser (Crystalaser, Reno, NV) emitted a 200 lm diameter band-pass filtered (BG3, Newport) ray perpendicular to a fused-silica glass micro-capillary (FS-110, Upchurch Scientific, ID¼100 lm, OD ¼ 300 lm) containing sample. Plastic coating on the capillary was removed with a blue flame and the capillary placed on a 561 UltrAlign precision linear stage (Newport Corp., Stratford, CT). Fluorescence emission filtered by a custom dichroic mirror (Andover, Salem, NH) to 320-400 nm, was detected by photomultiplier tube (R1166 PMT, Hamamatsu, Japan). The incident laser was split with a quartz slice (UQS Optics, Cambridge, UK), detected by PD (OSD5.8-7Q, RS components), and used to remove time-dependent source variations from the fluorescence emission. Both signals were processed via a PXI-5124 digitizer and Labview (National Instruments, Austin, TX). Samples were pumped through the capillary at 10 lL min À1 by syringe pump (KD Scientific Inc., Holliston, MA) and a 500 lL Hamilton gas-tight syringe, and samples measured and averaged for 100 laser pulses (corresponding to 16.7 nL of sample). Cleaning was applied between measurements using 1% Hellma (5 min, 10 lL min À1 ), 2% nitric acid (5 min, 10 lL min À1 ), an air flush, then sample buffer (5 min, 40 lL min À1 ). Fluorescence was determined immediately after the sample meniscus had passed. Baselines without protein were obtained and the final output signal (S) obtained from Eq. (1), where PMT and PD are the photomultiplier and PD signals:
S ¼ PMTðsampleÞ=PDðsampleÞ
ÀPMTðblankÞ=PDðblankÞ ð1Þ
Linearity and sensitivity to protein concentration for fluorescence intensity measured in the capillary
Twelve solutions of BSA at 0.015-75 lM were prepared in 60 mM sodium phosphate buffer, pH 7.0, and fluorescence intensities measured as described above.
Equilibrium denaturation of BSA measured using capillary fluorescence To 2 mL each of a range of urea solutions from 0 to 9 M in 50 mM Tris.HCl, pH 7.2 was added 100 lL 0.15 mM BSA stock (250 mg BSA in 25 mL 50 mM Tris.HCl, pH 7.2), giving final BSA concentrations of 7.14 lM. Samples were equilibrated for 17 hours at 22 C, consistent with the FKBP-12 experiments below. Fluorescence intensities were measured in the capillary as above, and then in a Fluostar Optima plate-reader (BMG Labtechnologies, Aylesbury, UK) with 280 nm excitation and 340 6 10 nm emission as previously described. 6, 7 Equilibrium denaturation of wild-type FKBP-12
We added 50 lL FKBP-12 stock (50 lM FKBP-12, 5 mM DTT, 50 mM Tris.HCl, pH 7.5) to each well of a UV transparent Costar (Corning, Lowell, MA) 96-well plate. Twenty-five concentrations of guanidine hydrochloride (GdnHCl) from 0 to 5.6 M, were created by varying the volumes of 0 M and 7 M GdnHCl stock solutions in 50 mM Tris.HCl pH 7.5, autotitrated in each well (Fluostar Optima) to a total of 200 lL. For rapamycin binding, the 0 M and 7 M GdnHCl stock solutions both contained 18.8 lM rapamycin (from a 54 mM stock in EtOH), giving a 15 lM final concentration. Samples were sealed and equilibrated for 17 hours at 22 C before measurement of intrinsic protein fluorescence in a Fluostar Optima plate reader as above. The same samples were then used to measure intrinsic protein 
Conclusions
Our experiments show for the first time that the intrinsic fluorescence of proteins can be used to accurately determine the thermodynamic parameters of protein stability for samples at low nanolitre volumes in a capillary with dimensions that are also typical of the channels used in microfluidic chips. Such a technique, easily implementable as an integrated biochip including on-board optics and microfluidics, could be used in the high-throughput formulation of protein therapeutics, or the screening of large libraries of protein engineered variants for improved stability. This is particularly facilitated by the use of flowing protein samples which both avoids the photobleaching effects associated with static samples and allows continuous processing with existing microfluidic mixer technologies. Indeed, we have demonstrated here [ Fig. 1(b) ] that sequences of bubbles containing various fluid mixtures can be prepared and then passed through a 1.5 nL fluorescence probe region. The dynamic range of the technique also permits measurements at protein concentrations from low physiologically relevant levels to the higher concentrations used in biopharmaceutical formulations. Finally, the associated microfluidics naturally enable serial or parallel testing of solution-based fluorescence alongside assays, such as SPR or micromechanical bending, 48 for interactions with surface-immobilized targets. For example, a single solution can be prepared to flow past a cantilever assay array and subsequently a fluorescence assay region. We have used the technique to perform a detailed biophysical analysis of the interaction of FKBP-12 with rapamycin and to specifically determine the energetic contribution of the interaction between a single residue and the rapamycin molecule. We show that the technique can be used to measure the interaction of small molecule drugs with a protein, without the need for protein or ligand labeling. This has significant potential for the high-throughput and low volume screening of combinatorial compound libraries against target proteins for drug discovery. The absence of a need for labeling makes the technique generically applicable to any protein target with intrinsic fluorescence, particularly from tryptophan residues.
